Skip to content

Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant

Small Feasibility Study for Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03111888
Enrollment
0
Registered
2017-04-13
Start date
2017-10-01
Completion date
2019-03-31
Last updated
2018-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emphysema, Pulmonary Disease, Chronic Obstructive

Brief summary

The goal of the small feasibility trial is to establish a method, material, and patient-specific design that is superior to what is in use today. The first round of patients are well known to the physician investigator and are familiar with the problem that is being resolved. The end goal of the project is to create a new patient-specific design that will last longer, fit better, and cause less trauma to the airway and the patient.

Detailed description

Subjects will be selected from physician investigator's clinical practice where patients have had failure of current stenting procedures to achieve an adequate clinical outcome. A routine CT scan of the chest is required on all individuals going through the procedure for stent placement (rigid bronchoscopy). The physician investigator will use this CT scan to measure and build a patient-specific stent or modify existing stents to fit the specific need.

Interventions

DEVICESilicone Stent Airway Implant

The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient-specific stent can be manufactured using rapid prototyping technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.

Sponsors

Custom Orthopaedic Solutions
CollaboratorUNKNOWN
The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Understand and voluntarily sign an informed consent form. 2. Patients must be at least 18 years of age 3. Patients must be able to undergo routine non-contrast CT scans of the chest 4. Patient must be stable for general anesthesia and have an airway amenable to rigid bronchoscopy and stent implantation. 5. The patients must have at least an expected 6 month survival. 6. Patient must be able to maintain standard of care follow-up schedule and have access to standard of care medications and nebulizer machines and/or suction and oxygen as required for primary disease management. 7. Patient must be able to personally provide consent and be able to describe Dyspnea and QOL and other patient-reported outcomes (PROs) required by study design 8. Patient must require a stent that is within the design envelope of the patient-specific stents, as defined by COS

Exclusion criteria

1. Patients may be excluded if the disease can be managed by simply removing prior stents or performing more conservative therapies. 2. Chronic anticoagulant therapy that could limit the safety of performing rigid therapeutic bronchoscopy in a timely manner. (I.e. Plavix within one year of drug eluding cardiac stent (DES)or 6 weeks following bare metal coronary stent) 3. Unstable cardiac disease 4. Allergy to silicone 5. Stenting to manage vascular compression syndromes. 6. Multi-drug resistant bacterial or fungal chronic infections 7. Emergent/urgent clinically indicated stent. 8. Chronic/permanent mechanical ventilation.

Design outcomes

Primary

MeasureTime frameDescription
Observe the outcomes associated with patient-specific airway implants.Up to 90 days following treatmentMeasure Quality of Life Index through Baseline Dyspnea Index, a validated survey tool

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026